Back

Disease-related baseline cerebrospinal fluid proteomic variation refines biomarker interpretation before CAR-T therapy

Nomiyama, T.; Setoyama, D.; Yamanaka, I.; Shimo, M.; Miyawaki, K.; Yamauchi, T.; Jinnouchi, F.; Sakoda, T.; Sasaki, K.; Nakagaki, H.; Takigawa, K.; Taniguchi, S.; Shima, T.; Mori, Y.; Kanaji, S.; Kato, T. A.; Kikushige, Y.; Akashi, K.; Kunisaki, Y.; Kato, K.

2026-08-24 hematology
10.64898/2026.08.22.26360883 medRxiv
Show abstract

Pre-infusion cerebrospinal fluid (CSF) proteomics may enable risk stratification for immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric antigen receptor T-cell therapy, but disease-specific baseline variation may influence biomarker interpretation. We compared pre-infusion CSF proteomic profiles from 28 patients with diffuse large B-cell lymphoma (DLBCL) and 9 with multiple myeloma (MM). Although principal component analysis showed substantial overlap, orthoPLS-DA identified significant disease-associated discrimination supported by permutation testing. Proteins contributing to this separation were enriched for plasma cell-related, extracellular, and metabolic signatures. ICANS occurred in 7 of 28 DLBCL patients but in none of the 9 MM patients. MM cases aligned with the ICANS-negative group in binary analysis while remaining distinct from both DLBCL subgroups in three-group analysis. These findings indicate that pre-infusion CSF proteomics captures disease-specific molecular structure that should be considered when developing and interpreting biomarkers of CAR-T-associated neurotoxicity.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.